MiR-143-3p silencing participates in the development of obesity-mediated insulin resistance, glucose tolerance and lipid accumulation and characterizes the miR-143-3p-IGF2R cascade as a possible target of treating obesity-linked metabolic diseases (Xihua et al., 2019). The gene discussed is IGF2R; the disease is obesity disorder.